Targeting the B-cell receptor signaling pathway in B lymphoid malignancies
M Buchner, M Müschen - Current opinion in hematology, 2014 - journals.lww.com
M Buchner, M Müschen
Current opinion in hematology, 2014•journals.lww.comTargeting of the B-cell receptor tyrosine kinases spleen tyrosine kinase, Bruton's tyrosine
kinase, and phosphatidylinositol 3-kinase achieve promising clinical responses in various
mature B-cell malignancies and might also be useful in defined subsets of ALL. However,
further understanding of the BCR signal integration in the different disease groups is
required to accurately predict which groups of patients will benefit from BCR pathway
inhibition.
kinase, and phosphatidylinositol 3-kinase achieve promising clinical responses in various
mature B-cell malignancies and might also be useful in defined subsets of ALL. However,
further understanding of the BCR signal integration in the different disease groups is
required to accurately predict which groups of patients will benefit from BCR pathway
inhibition.
Summary
Targeting of the B-cell receptor tyrosine kinases spleen tyrosine kinase, Bruton's tyrosine kinase, and phosphatidylinositol 3-kinase achieve promising clinical responses in various mature B-cell malignancies and might also be useful in defined subsets of ALL. However, further understanding of the BCR signal integration in the different disease groups is required to accurately predict which groups of patients will benefit from BCR pathway inhibition.
Lippincott Williams & Wilkins